Multi‑omics approach to improve patient‑tailored therapy using immune checkpoint blockade and cytokine‑induced killer cell infusion in an elderly patient with lung cancer: A case report and literature review

Xing,Yasi; Qin,Fangyuan; Han,Lei; Yang,Jingwen; Zhang,Hongrui; Qi,Yong; Tu,Shichun; Zhai,Yaping

doi:10.3892/ol.2024.14334

Multi‑omics approach to improve patient‑tailored therapy using immune checkpoint blockade and cytokine‑induced killer cell infusion in an elderly patient with lung cancer: A case report and literature review

Authors:
- Yasi Xing
- Fangyuan Qin
- Lei Han
- Jingwen Yang
- Hongrui Zhang
- Yong Qi
- Shichun Tu
- Yaping Zhai
View Affiliations

Affiliations: Henan Eye Institute, Henan Eye Hospital, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, Henan 450001, P.R. China, Zhengzhou Shenyou Biotechnology, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, Henan 450001, P.R. China, Department of Respiratory and Critical Care Medicine, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, Henan 450001, P.R. China
Published online on: March 11, 2024 https://doi.org/10.3892/ol.2024.14334
Article Number: 203
Copyright: © Xing et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The 5‑year survival rate of patients with advanced non‑small cell lung cancer (NSCLC) remains low, despite recent advances in targeted therapy and immunotherapy. Therefore, there is a need to identify alternative strategies to improve treatment outcomes. Modern diagnostics can significantly facilitate the selection of treatment plans to improve patient outcomes. In the present study, multi‑form diagnostic methodologies were adopted, including next‑generation sequencing‑based actionable gene sequencing, programmed death ligand 1 (PD‑L1) immunohistochemistry, a circulating tumor cell (CTC) assay, flow cytometric analysis of lymphocyte subsets and computed tomography, to improve disease management in an 86‑year‑old female patient with relapsed metastatic NSCLC. High expression of PD‑L1, elevated CTC tmutations, were observed. Based on these results, the patient was initially treated with the programmed death protein 1 blocking antibody sintilimab for two cycles, resulting in the stabilization of their condition, although the patient still exhibited severe pain and other symptoms, including fatigue, malaise, a loss of appetite and poor mental state. Informed by dynamic monitoring of the patient's response to treatment, the treatment plan was subsequently adjusted to a combination therapy with sintilimab and autologous cytokine‑induced killer cell infusion, which eventually led to improved outcomes in both the management of the cancer and quality of life. In conclusion, multi‑omics analysis may be used to establish patient‑tailored therapies to improve clinical outcomes in hard‑to‑treat elderly patients with metastatic NSCLC.

View Figures

View References

1	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
2	Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A and Bray F: Cancer statistics for the year 2020: An overview. Int J Cancer. 149:778–789. 2021. View Article : Google Scholar
3	Sosa E, D'Souza G, Akhtar A, Sur M, Love K, Duffels J, Raz DJ, Kim JY, Sun V and Erhunmwunsee L: Racial and socioeconomic disparities in lung cancer screening in the United States: A systematic review. CA Cancer J Clin. 71:299–314. 2021. View Article : Google Scholar : PubMed/NCBI
4	Khanna P, Blais N, Gaudreau PO and Corrales-Rodriguez L: Immunotherapy comes of age in lung cancer. Clin Lung Cancer. 18:13–22. 2017. View Article : Google Scholar : PubMed/NCBI
5	Spagnuolo A and Gridelli C: The role of immunotherapy in the first-line treatment of elderly advanced non-small cell lung cancer. Cancers (Basel). 15:23192023. View Article : Google Scholar : PubMed/NCBI
6	Xia L, Liu Y and Wang Y: PD-1/PD-L1 blockade therapy in advanced non-small-cell lung cancer: Current status and future directions. Oncologist. 24 (Suppl 1):S31–S41. 2019. View Article : Google Scholar : PubMed/NCBI
7	Momotow J, Bühnen I, Trautmann-Grill K, Kobbe G, Hahn D, Schroers R, Heinrich B, Gaska T, Forstbauer H, Schmidt B, et al: Outcomes of anti-programmed death 1 treatment for relapsed/refractory Hodgkin lymphoma: A German Hodgkin Study Group multicentre real-world analysis. Br J Haematol. 198:401–404. 2022. View Article : Google Scholar : PubMed/NCBI
8	Pan D, Hu AY, Antonia SJ and Li CY: A Gene mutation signature predicting immunotherapy benefits in patients with NSCLC. J Thorac Oncol. 16:419–427. 2021. View Article : Google Scholar : PubMed/NCBI
9	Hoffner B, Leighl NB and Davies M: Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer. Cancer Treat Rev. 85:1019792020. View Article : Google Scholar : PubMed/NCBI
10	Yi M, Zheng X, Niu M, Zhu S, Ge H and Wu K: Combination strategies with PD-1/PD-L1 blockade: Current advances and future directions. Mol Cancer. 21:282022. View Article : Google Scholar : PubMed/NCBI
11	Huang K, Sun B, Luo N, Guo H, Hu J and Peng J: Programmed death receptor 1 (PD1) knockout and human telomerase reverse transcriptase (hTERT) transduction can enhance persistence and antitumor efficacy of cytokine-induced killer cells against hepatocellular carcinoma. Med Sci Monit. 24:4573–4582. 2018. View Article : Google Scholar : PubMed/NCBI
12	Dehno MN, Li Y, Weiher H and Schmidt-Wolf IGH: Increase in efficacy of checkpoint inhibition by cytokine-induced-killer cells as a combination immunotherapy for renal cancer. Int J Mol Sci. 21:30782020. View Article : Google Scholar : PubMed/NCBI
13	Chen J, Chen Y, Feng F, Chen C, Zeng H, Wen S, Xu X, He J and Li J: Programmed cell death protein-1/programmed death-ligand 1 blockade enhances the antitumor efficacy of adoptive cell therapy against non-small cell lung cancer. J Thorac Dis. 10:6711–6721. 2018. View Article : Google Scholar : PubMed/NCBI
14	Poh SL and Linn YC: Immune checkpoint inhibitors enhance cytotoxicity of cytokine-induced killer cells against human myeloid leukaemic blasts. Cancer Immunol Immunother. 65:525–536. 2016. View Article : Google Scholar : PubMed/NCBI
15	Liu LW, Yang MY, Zhou M, Li JJ, Liu B and Pan YY: Improvement of cytotoxicity of autologous CIKs from patients with breast cancer to MCF-7 cells by suppressed PD-1 expression. Cancer Biomark. 20:609–615. 2017. View Article : Google Scholar : PubMed/NCBI
16	Han Y, Mu D, Liu T, Zhang H, Zhang J, Li S, Wang R, Du W, Hui Z, Zhang X and Ren X: Autologous cytokine-induced killer (CIK) cells enhance the clinical response to PD-1 blocking antibodies in patients with advanced non-small cell lung cancer: A preliminary study. Thorac Cancer. 12:145–152. 2021. View Article : Google Scholar : PubMed/NCBI
17	Wang Z, Liu X, Till B, Sun M, Li X and Gao Q: Combination of cytokine-induced killer cells and programmed cell death-1 blockade works synergistically to enhance therapeutic efficacy in metastatic renal cell carcinoma and non-small cell lung cancer. Front Immunol. 9:15132018. View Article : Google Scholar : PubMed/NCBI
18	Zhao L, Han L, Zhang Y, Li T, Yang Y, Li W, Shang Y, Lin H and Gao Q: Combination of PD-1 blockade and RetroNectin^®-activated cytokine-induced killer in preheavily treated non-small-cell lung cancer: A retrospective study. Immunotherapy. 10:1315–1323. 2018. View Article : Google Scholar : PubMed/NCBI
19	Pievani A, Borleri G, Pende D, Moretta L, Rambaldi A, Golay J and Introna M: Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. Blood. 118:3301–3310. 2011. View Article : Google Scholar : PubMed/NCBI
20	Mata-Molanes JJ, Sureda González M, Valenzuela Jiménez B, Martínez Navarro EM and Brugarolas Masllorens A: Cancer immunotherapy with cytokine-induced killer cells. Target Oncol. 12:289–299. 2017. View Article : Google Scholar : PubMed/NCBI
21	Zhang X, Huang H, Han L, Li T, Wang Z and Gao Q: Advanced renal-cell carcinoma pseudoprogression after combined immunotherapy: Case report and literature review. Front Oncol. 11:6404472021. View Article : Google Scholar : PubMed/NCBI
22	Zhao L, Li T, Song Y, Yang Y, Ma B, Zhang Y, Shang Y, Xu B, Guo J, Qin P, et al: High complete response rate in patients with metastatic renal cell carcinoma receiving autologous cytokine-induced killer cell therapy plus anti-programmed death-1 agent: A single-center study. Front Immunol. 12:7792482022. View Article : Google Scholar : PubMed/NCBI
23	Sharma A and Schmidt-Wolf IGH: 30 Years of CIK cell therapy: Recapitulating the key breakthroughs and future perspective. J Exp Clin Cancer Res. 40:3882021. View Article : Google Scholar : PubMed/NCBI
24	Gao S, Li N, Gao S, Xue Q, Ying J, Wang S, Tao X, Zhao J, Mao Y, Wang B, et al: Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC. J Thorac Oncol. 15:816–826. 2020. View Article : Google Scholar : PubMed/NCBI
25	Zhang F, Guo W, Zhou B, Wang S, Li N, Qiu B, Lv F, Zhao L, Li J, Shao K, et al: Three-year follow-up of neoadjuvant programmed cell death protein-1 inhibitor (Sintilimab) in NSCLC. J Thorac Oncol. 17:909–920. 2022. View Article : Google Scholar : PubMed/NCBI
26	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
27	Helling M and Venulet J: Drug recording and classification by the WHO research centre for international monitoring of adverse reactions to drugs. Methods Inf Med. 13:169–178. 1974. View Article : Google Scholar : PubMed/NCBI
28	Vaseq R, Sharma A, Li Y and Schmidt-Wolf IGH: Revising the landscape of cytokine-induced killer cell therapy in lung cancer: Focus on immune checkpoint inhibitors. Int J Mol Sci. 24:56262023. View Article : Google Scholar : PubMed/NCBI
29	Feng Y, Feng G, Lu X, Qian W, Ye J, Manrique CA, Ma C and Lu Y; written on behalf of the AME Lung Cancer Collaborative Group, : Exploratory analysis of introducing next-generation sequencing-based method to treatment-naive lung cancer patients. J Thorac Dis. 10:5904–5912. 2018. View Article : Google Scholar : PubMed/NCBI
30	Tsoulos N, Papadopoulou E, Metaxa-Mariatou V, Tsaousis G, Efstathiadou C, Tounta G, Skapeti K, Bourkoula J, Zarogoulidis P, Pentheroudakis GE, et al: Molecular profiling of 502 patient cohort with NSCLC using a 27 somatic gene panel. J Clin Oncol. 35:e231932017. View Article : Google Scholar
31	Xing Y, Qin F, Zhai Y, Yang J, Yan Y, Li D, Zhang H, Hu R, Xu X, Cao X, et al: Association of clinical features of colorectal cancer with circulating tumor cells and systemic inflammatory markers. Dis Markers. 2022:51055992022. View Article : Google Scholar : PubMed/NCBI
32	Xing Y, Zhang X, Qin F, Yang J, Ai L, Wang Q and Zhai Y: The clinical significance of circulating tumor cells and T lymphocyte subtypes in pancreatic cancer patients. Bioengineered. 13:2130–2138. 2022. View Article : Google Scholar : PubMed/NCBI
33	Yang X, Jiang L, Jin Y, Li P, Hou Y, Yun J, Wu C, Sun W, Fan X, Kuang D, et al: PD-L1 expression in chinese patients with advanced non-small cell lung cancer (NSCLC): A multi-center retrospective observational study. J Cancer. 24:7390–7398. 2021. View Article : Google Scholar : PubMed/NCBI
34	Poondla N, Sheykhhasan M, Akbari M, Samadi P, Kalhor N and Manoochehri H: The promise of CAR T-cell therapy for the treatment of cancer stem cells: A short review. Curr Stem Cell Res Ther. 17:400–406. 2022. View Article : Google Scholar : PubMed/NCBI
35	Tang Q, Zuo W, Wan C, Xiong S, Xu C, Yuan C, Sun Q, Zhou L and Li X: Comprehensive genomic profiling of upper tract urothelial carcinoma and urothelial carcinoma of the bladder identifies distinct molecular characterizations with potential implications for targeted therapy & immunotherapy. Front Immunol. 13:10977302023. View Article : Google Scholar : PubMed/NCBI
36	Weber J: Immune checkpoint proteins: A new therapeutic paradigm for cancer-preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol. 37:430–439. 2010. View Article : Google Scholar : PubMed/NCBI
37	Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL, et al: MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 515:558–562. 2014. View Article : Google Scholar : PubMed/NCBI
38	Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, et al: Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 515:563–567. 2014. View Article : Google Scholar : PubMed/NCBI
39	Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, et al: PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 515:568–571. 2014. View Article : Google Scholar : PubMed/NCBI